Dr. Kradin's primary affiliations are as a member of the Pulmonary Pathology subspecialty service in the Pathology Department, and the Pulmonary and Critical Care Medicine division at Mass General Hospital.
Dr. Kradin's career has integrated formal training in pulmonary medicine, anatomic pathology, basic immunology, and psychiatry. Dr. Kradin's primary area of expertise is the immunopathology of lung disease, to which he has made significant contributions in the areas of antigen processing by dendritic cells, and the immunopathogenesis of acute and chronic interstitial lung injury.
Dr. Kradin has contributed articles and texts in areas as diverse as infectious disease, meditation, and psychosomatic medicine. His concomitant practice of medicine and pathology allowed him to develop an NIH-funded clinical trial of the adoptive transfer of autologous tumor-specific activated lymphocytes and interleukin-2 in the treatment of advanced cancers. This was a pioneering study in the effort to "personalize" cancer treatment, and elements of this approach continue to be adopted by oncologists in the treatment of patients with advanced malignant melanoma and renal cell carcinoma.
Read more in Chapter 23, Immunopathology in Keen Minds to Explore the Dark Continents of Disease, a history of Pathology at Massachusetts General Hospital.
Dr. Kradin's research efforts have included the description of several new diseases, including nodular pulmonary lymphoid hyperplasia, a benign lymphoid hyperplasia seen in HIV-infections and numerous autoimmune disorders; a clinical variant of diffuse alveolar damage with features of organizing pneumonia seen in patients with ARDS that respond favorably to corticosteroids; a variant of alveolar lipoproteinosis that requires distinct therapeutic intervention; an accelerated clinical form of asbestosis; a form of interstitial lung disease that accompanies myelodysplasia and augurs leukemic transformation; and a novel malignant tumor of the lung (pulmonary blastoma). Research interests include pulmonary pathology, pulmonary immunity, infectious disease, stress and immunity, and asbestos-related disease.
Research techniques include tissue culture and immunocytochemistry, flow cytometry, Northern blotting, and immunocytochemistry. Dr. Kradin's research projects range from basic science to clinical research. For more information about research concepts, co-authors, timeline, and more visit Dr. Kradin's profile at the Harvard Clinical and Translational Science Center.